US Senators Probe Links Between Opioid Manufacturers and Medical Groups - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

US Senators Probe Links Between Opioid Manufacturers and Medical Groups


ePT--the Electronic Newsletter of Pharmaceutical Technology

Senators Max Baucus (D-MT) and Chuck Grassley (R-IA) are probing ties between manufacturers of opioid painkillers and medical groups that have advocated for increased use of such drugs for pain management. The intent of the probe is to establish the extent of financial ties between the two to determine whether there has been undue influence of industry on prescribing practices. The impetus for the probe is the high rate of abuse of prescription opioids, and the dangers such drugs pose. According to a press release from the two senators, deaths from painkiller overdoses have tripled over the last decade and led to the deaths of 14,800 Americans in 2008, exceeding those caused by heroin and cocaine combined.

Letters were sent to Perdue Pharma, Endo Pharmaceuticals, and Johnson & Johnson, asking them to disclose financial ties to 10 medical groups and eight individuals who played a prominent role in setting pain management guidelines. The companies were also asked to provide all communications in regard to the book Responsible Opioid Prescribing: A Physician's Guide, distributed by the Federation of State Medical Boards, and communications in regard to the pain management guidelines published by several medical groups.

The Senators also sent letters to the American Pain Foundation, the American Academy of Pain Medicine, the American Pain Society, the Center for Practical Bioethics, the Wisconsin Pain and Policy Study Group, the Joint Commission on Accreditation of Healthcare Organizations, and the Federation of State Medical Boards asking them to disclose financial support from any company that develops, manufactures, or distributes opioid pain medications.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here